Business Context and Reporting Period
This Form 8-K is a current report filed by Bristol-Myers Squibb Company on February 10, 2021. The filing primarily addresses corporate governance changes regarding the Board of Directors ahead of the 2021 Annual Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
- Board Departures: Dr. Vicki Sato, Mr. Robert Bertolini, and Mr. Matthew Emmens notified the company they will not stand for re-election to the Board of Directors at the 2021 Annual Meeting.
- Board Size Reduction: The Board of Directors set the number of directors at eleven, effective as of the 2021 Annual Meeting.
Outlook and Management Commentary
The 2021 Annual Meeting of Shareholders is expected to be held on May 4, 2021. No specific financial guidance, risk factors, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the 2021 Annual Meeting.
- Confirm the reduction of the Board size to eleven members.
- Note that this filing does not contain financial results; refer to the most recent 10-Q or 10-K for financial metrics.